Phase II and Pharmacodynamic Study of PS-341 in Patients With Unresectable or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Biliary cancer; Gallbladder cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 May 2017 Status changed from completed to discontinued.
- 28 Nov 2012 Actual end date changed from Apr 2009 to Jan 2009 as reported by ClinicalTrials.gov.